Ascendis Pharma’s TransCon CNP Wins CHMP Backing for Pediatric Achondroplasia

EMA’s CHMP recommended Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged 2 and older with open growth plates. A European Commission decision is expected in the fourth quarter of 2026. Subject to approval, the first EU launch under the YUVIWEL brand is planned in Germany for the first quarter of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via (Ref. ID: 202610170952OMX_____CNEWS_DE_GNW9847835_de) on October 17, 2026, and is solely responsible for the information contained therein. (C)